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Purpose: Stereotactic body radiation therapy (SBRT) for pancreatic cancer requires a skillful approach to
deliver ablative doses to the tumor while limiting dose to the highly sensitive duodenum, stomach, and small
bowel. Here, we develop knowledge-based artificial neural network dose models (ANN-DMs) to predict dose
distributions that would be approved by experienced physicians.
Methods: Arc-based SBRT treatment plans for 43 pancreatic cancer patients were planned, delivering
30-33 Gy in five fractions. Treatments were overseen by one of two physicians with individual treatment
approaches, with variations in prescribed dose, target volume delineation, and primary organs-at-risk. Using
dose distributions calculated by a commercial treatment planning system (TPS), physician-approved treat-
ment plans were used to train ANN-DMs that could predict physician-approved dose distributions based on
a set of geometric parameters (vary from voxel to voxel) and plan parameters (constant across all voxels for
a given patient). Patient datasets were randomly allocated, with 2/3rds used for training, and 1/3rd used
for validation. Differences between TPS and ANN-DM dose distributions were used to evaluate model per-
formance. ANN-DM design, including neural network structure and parameter choices, were evaluated to
optimize dose model performance.
Results: Remarkable improvements in ANN-DM accuracy (i.e., from >30% to <5% mean absolute dose
error, relative to the prescribed dose) were achieved by training separate dose models for the treatment style
of each physician. Increased neural network complexity (i.e., more layers, more neurons per layer) did not
improve dose model accuracy. Mean dose errors were less than 5% at all distances from the PTV, and mean
absolute dose errors were on the order of 5%, but no more than 10%. Dose-volume histogram errors (in cm3)
demonstrated good model performance above 25 Gy, but much larger errors were seen at lower doses.
Conclusions: ANN-DM dose distributions showed excellent overall agreement with TPS dose distributions,
and accuracy was substantially improved when each physicians treatment approach was taken into account by
training their own dedicated models. In this manner, one could feasibly train ANN-DMs that could predict
the dose distribution desired by a given physician for a given treatment site.
This manuscript was submitted to Medical Physics
I. INTRODUCTION
Pancreatic cancer is a devastating disease with an ex-
tremely high mortality. Over the past decades, treatment
for early-to-mid stage pancreatic cancer has evolved sig-
nificantly. The best results are seen in patients who are
able to undergo surgery, with five-year survival rates of
20-25% and 4-6% with and without surgery, respectively
[1, 2]. Recently, stereotactic body radiation therapy
(SBRT) has emerged as a favorable option for patients
with locally advanced or borderline resectable pancreatic
adenocarcinoma [38]. SBRT is an aggressive local ther-
apy that has improved outcomes in other hard-to-treat
tumors, such as non-small cell lung cancer, melanoma,
and renal cell carcinoma [9, 10]. By delivering large, ab-
lative doses of radiation in only a few treatment fractions,
SBRT leads to significantly improved local control [11].
However, much like surgical techniques, SBRT is a chal-
lenging form of local therapy that requires precision to
achieve favorable outcomes.
a)Author to whom correspondence should be addressed:
bernard.jones@ucdenver.edu
Pancreatic cancer patients who undergo surgical re-
section of their tumor typically receive a pancreatico-
duodenectomy. This procedure involves the surgical re-
section of the head of the pancreas, the duodenum, the
gallbladder, and often the distal portion of the stomach.
The remaining anatomy is then reassembled to allow bile
from the liver and digestive enzymes from the residual
pancreas to drain into what remains of the small bowel,
helping the patient retain some digestive function.
Our ability to safely perform this surgery today is a
result of more than a century of work. Often referred
to as the Whipple procedure, the origins of the modern
day pancreaticoduodenectomy are often traced back to a
seminal 1935 paper by Whipple, Parsons, and Mullins,
in which they presented the procedure as it was per-
formed on three patients [12]. However, the first reported
pancreaticoduodenectomy for pancreatic cancer was per-
formed nearly four decades prior in 1898 by Alessandro
Codivilla for a case in which the patient died 21 days
later from cachexia [13]. In subsequent years, important
developments were made before Whipple would refine the
procedure, including insights into duodenal function and
drainage within the gastrointestinal system [14]. Still,
at the time of Whipples death in 1963, the surgery re-
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2mained controversial due to its high morbidity and mor-
tality rates [15, 16]. A 1966 review by Morris and Nardi
was more hopeful, emphasizing that if mortality rates
for the operation (20-40% at the time) could be reduced,
then a more optimistic picture of the procedure could be
painted [17]. Today, after decades of refinement, pan-
creaticoduodenectomy mortality rates have reduced sub-
stantially (as low as 1%) [18]. Even so, expertise and
experience still play an important role. Mortality rates
are significantly higher at low-volume facilities compared
to high-volume facilities [19]. As such, significant value
must still be attributed to the skills of the surgeon.
Here, we argue that radiation therapys role in the
treatment of pancreatic cancer is following a path par-
allel to the path for the pancreaticoduodenectomy. Akin
to broad improvements to surgical procedures in gen-
eral, techniques and technologies involved in radiation
delivery have advanced rapidly in recent decades. Yet,
there is still significant variability between treatments at
different centers. Abrams et al recently examined the
role that adherence to radiation therapy protocol played
in outcomes for the Radiation Therapy Oncology Group
(RTOG) 9704 phase III trial for pancreatic cancer, and
they found that failure to adhere to protocol was signif-
icantly associated with reduced median survival [20]. In
theory, inverse planning should result in treatment with
an optimal plan, yet studies have shown significant vari-
ations between planners [21]. Also, similar to surgery,
Amini et al found significant differences in survival for
complex radiotherapy to the anal canal between high and
low-volume centers [22].
One avenue for refining our approach to pancreatic
SBRT is knowledge-based planning, which seeks to utilize
information gained from prior radiation therapy treat-
ment plans, including the specific challenges of a given
anatomical location, to help guide and improve the radi-
ation therapy planning process. Currently, most pub-
lished data regarding the efficacy of pancreatic SBRT
come from single-institution studies [4-8]. In an ideal
world, it would be possible for centers with experience
with this technique to disseminate data regarding how
to achieve the best results. However, in practice, this
is often challenging. Recently, Shiraishi and Moore de-
veloped a 3D dose-prediction model that uses artificial
neural networks to predict the resulting dose distribution
based on patient anatomy [23]. In this paper, we develop
a similar dose-prediction model for pancreatic SBRT, for
which 3D dose-prediction is important due to the close
proximity to highly sensitive organs at risk.
The purpose of this work is to test the feasibility of us-
ing knowledge-based planning for 3D dose-prediction in
pancreatic SBRT. We develop artificial neural network
dose models (ANN-DMs) to calculate desirable dose dis-
tributions for pancreatic cancer patients receiving arc-
based SBRT. Models calculate dose according to geomet-
ric and plan parameters, and each model was trained us-
ing previous treatment plans and dose distributions at
our institution. To demonstrate the appropriateness of
these models, we also developed models of increased or
decreased complexity. In order to guide parameter se-
lection in future models, we also evaluated the relative
importance of different parameters within the model. Ul-
timately, we are not advocating that the treatment ap-
proaches prescribed in this work are the best approaches
for pancreatic SBRT. Rather, we intend to build a frame-
work for the objective comparison of pancreatic SBRT
plans that are meant to comply with an established set
of treatment guidelines.
II. METHODS
A. Patient Data
Data were collected from 43 patients with locally ad-
vanced, borderline resectable, or recurrent pancreatic tu-
mors treated at our institution using arc-based SBRT.
These retrospective data were collected under an in-
ternal review board-approved protocol to analyze novel
methods in patient dosimetry. Planning target vol-
umes (PTVs) were formed via a 0-5 mm patient-specific
anisotropic expansion from physician-defined clinical tar-
get volumes (CTVs). Median (±σ) PTV was 110 (±77)
cm3. Tumors were prescribed to receive maximum doses
of 30-33 Gy in five fractions, delivered using 2-4 copla-
nar arcs spanning 250-360 degrees. Patient immobiliza-
tion and repositioning was achieved using Alpha Cradle
expanding foam forming molds (Smithers Medical Prod-
ucts, Inc.; North Canton, OH). Tumor motion was man-
aged using either abdominal compression or respiratory
gating.
Patients were treated by one of two physicians, each
with an individualized treatment approach. As such, two
distinct groups of patients were identified. In Group A
(29 patients), two treatment volumes were specified: a
larger PTV prescribed to receive 20 Gy, and a smaller,
gross tumor volume (GTV) prescribed to receive 30 Gy.
In Group B (14 patients), a single treatment volume, the
PTV, was prescribed to receive 33 Gy. Primary organs at
risk (OARs) for both Groups A and B are listed in Table
I, along with contouring guidelines and dose constraints.
Select OARs were contoured according to specific RTOG
guidelines [24].
B. Artificial Neural Network Dose Models
Artificial neural networks can feature multiple hidden
layers between an input layer and an output layer, and
each hidden layer can include multiple nodes. A simple
example of an artificial neural network is depicted in Fig-
ure 1, which features two inputs, one hidden layer with
three nodes, and a single output. The activation value
for each hidden node is determined by taking a weighted
sum of the input values (or, for multi-layer networks, the
3Group A
Organ Contouring Guidelines Constraint
Stomach* Includes: cardia (begins at GEJ), fundus (most cephalad, abuts left hemi-
diaphragm, left & superior to cardia), body (central, largest portion),
antrum (gateway to the pylorus).
Stomach minus PTV: Max point
dose < 30 Gy
Bowel Bag Loops of small and large bowel and interdigitating mesentery delineated
on axial CT slices. Excludes bone, muscle, separate abdominal organs
(i.e., kidney, stomach, liver). Includes duodenum.
Bowel minus PTV: Max point dose
< 30 Gy; V20 < 50 cm3
Spinal Cord Contoured based on the bony confines of the spinal cord. Max point dose < 10 Gy
Liver* Gallbladder should be excluded. IVC should be excluded when discrete
from liver. PV should be included in liver contour when caudate lobe is
seen to left of PV.
Mean dose < 10 Gy
Kidneys Both right and left kidney are contoured in their entirety. V15 < 20%
Group B
Organ Contouring Guidelines Constraint
Stomach* Same as in Group A. Stomach minus PTV: V33 < 1
cm3, V20 < 3 cm3, V15 < 9 cm3
Duodenum* First portion: begins after pylorus, retroperitoneal after first 5 cm where
it is suspended by hepatoduodenal ligament. Second (descending) portion:
starts at superior duodenal flexure, attached to head of pancreas, 7.5 cm
long, located to right of IVC at levels L1-L3. Third (transverse) portion:
crosses in from of aorta & IVC and is posterior to SMA & SMV, 10
cm long, marks end of C-loop of duodenum. Fourth (ascending) portion:
travels superiorly until it is adjacent to inferior pancreatic body, 2.5 cm
long, lies anteriorly to the IMV until the IMV moves medially at the
transition to the jejunum.
Duodenum minus PTV: V33 < 1
cm3, V20 < 3 cm3, V15 < 9 cm3
Small Bowel Loops of small bowel initiating at the jejunum (end of fourth portion of the
duodenum) and extending to the start of the ascending colon. Excludes
the duodenum, which is contoured separately.
Small Bowel minus PTV: V33 < 1
cm3, V20 < 3 cm3, V15 < 9 cm3
Large Bowel Includes ascending, transverse, descending colon loops. Terminates at the
rectum.
Large Bowel minus PTV: V33 < 5
cm3, V20 < 10 cm3, V15 < 15 cm3
Spinal Cord Same as in Group A. V15 < 1 cm3
Liver* Same as in Group A. Liver minus GTV: D50% < 12 Gy
Kidney Same as in Group A. V15 < 35%
TABLE I. Organs at risk, OAR contouring guidelines, and dose constraints for patients in Group A and Group B. GEJ:
gastroesophageal junction, IVC: inferior vena cava, PV: portal vein, SMA: superior mesenteric artery, SMV: superior mesenteric
vein, IMV: inferior mesenteric vein. *Contouring per RTOG guidelines.
set of nodes in the previous hidden layer) and then enter-
ing that weighted sum into an activation function (e.g., a
sigmoid function). After activation values are calculated
for each node in a layer, activation values for the subse-
quent layer (in this case, the output node) are calculated
in a similar fashion. All weight values that interconnects
nodes of one layer to nodes of the next layer are inde-
pendent of one another, and these values are adjusted as
the neural network is trained. Initially, all weight val-
ues are chosen randomly. Then, by providing training
data (i.e., input values with known output values), er-
ror magnitudes observed at the output layer determine
how weights should be adjusted, typically through back-
propagation. This routine is repeated multiple times us-
ing known datasets until weight adjustments no longer
have discernible effects on error size. Then, a validation
dataset (i.e., input values with known output values that
were not used during training) is used to assess the net-
works performance.
For each patient, a volume of interest was defined as
all voxels within 100 mm of the surface of the PTV. Each
individual voxel in the volume of interest could then be
used to provide input data for an artificial neural network
that would produce a single output value: dose to that
voxel. Input values were either geometric parameters or
plan parameters. Geometric parameters are factors such
as the voxels distance to the PTV surface, distance to an
OAR, or the number of arcs directly impinging on the
voxel. Plan parameters are factors such as the photon
beam energy or PTV volume. Geometric parameters can
differ for each voxel within a given patient, whereas plan
parameters are equal for all voxels in a single patient,
but can differ between patients. The initial parameters
used for this work are listed in Table II and are described
in more detail below. Ultimately, four main ANN-DMs
were developed: a pair of models each for Group A and
4FIG. 1. Left: diagram showing a simple artificial neural network with two inputs, a hidden layer with three nodes, and one
output. Right: a more detailed depiction of how the activation value of a single node, aj, is calculated. A weighted sum of all
activation values from the prior layer plus a bias value is indicated here by xj. This value is then entered into g, an activation
function (e.g. we used log-sigmoid functions). Inter-node weight values (i.e., wij, wjk, etc.) are independent of one another,
and these values are adjusted as the neural network is trained.
Group B, with a model for within the treated volume,
and a model for outside the treated volume.
C. Geometric Parameters
In general, all voxels were categorized into two main
regions: (1) in slice voxels, which include all voxels that
lie in an axial slice that contains at least some portion
of the PTV, and (2) out of slice voxels, which include all
other voxels.
The primary parameter in the geometric model is
rptv3D, the shortest 3D distance from the voxel to the
PTV surface. This factor was meant to capture the gen-
eral shape of the dose gradient outside the target. A re-
lated parameter, rptv2D, describes the axial distance from
the voxel to the PTV surface (i.e., the shortest distance
ignoring the superior-inferior displacement). Inclusion of
this factor allows for more accurate differentiation in the
model between voxels inside and outside treated slices
(i.e., slices that include at least a portion of the treat-
ment volume). Parameter zin is the normalized superior-
inferior (SI) distance from the voxel to the PTV centroid
for voxels within the treated slice (i.e., ranging from 0
for voxels in the central PTV slice to 1 for voxels in the
most superior or most inferior PTV slice). This factor
captures photon scatter effects between slices. Parameter
zout is the normalized SI distance to the PTV (normal-
ized relative to PTV height) for voxels out-of-slice with
the target, and this helps to further characterize the scat-
ter distribution outside of the direct beam. The depth
parameter, rsurf, is the distance from the voxel to the pa-
tient surface along the axis between the voxel and the
PTV. The arc factor, Farc, is a binary parameter that
describes whether a voxel lies in the direct path of an
incoming treatment beam. Most plans examined in this
study used 360◦ arcs, but some plans used anterior arcs
that do not directly irradiate posterior regions such as
the kidneys or spinal cord. The parameter θ is the an-
gle within the axial plane, calculated with respect to the
PTV centroid. Three geometric parameters specific to
the pancreas were also included in each patient group for
better dose model performance. The majority of these
parameters were selected based on the OARs nearest the
target volumes. Both Group A and Group B included rst,
the shortest distance between the voxel and the stomach
volume. Group A also included a second OAR factor,
rbb, which is the shortest distance between the voxel and
the bowel bag volume. An additional factor in Group
A, rgtv, describes the shortest distance between the voxel
and the GTV, and captures the effect of the multiple dose
prescription levels in Group A plans. Group B patients
included two additional OAR factors: rduo and rsb, which
respectively are the shortest distances between the voxel
and the duodenum volume and small bowel volume. For
all distance-to-volume based geometric parameters, dis-
tance values are negative when voxels occur within the
volume in question.
D. Plan Parameters
Two plan parameters were chosen to capture broad
differences between plans for different patients. The first
parameter, Vptv , denotes the volume of the PTV in cm
3.
The second parameter, E, indicates the photon energy
used for treatment, either 6 MV, 10 MV, or 10 MV in
flattening filter free (FFF) mode. Two additional plan
parameters were eliminated when patients were divided
into two separate groups. First eliminated was Rx, which
indicated the prescribed maximum dose. Second elimi-
nated was MD, which indicated the identity of the ap-
proving physician. The factor MD was initially consid-
ered in order to account for differences in physician treat-
5Parameter Name Description Min Max Units
All
ag1 rptv3D Shortest 3D distance to PTV -24.7 100.9 mm
ag2 rptv2D Axial component of rptv3D -25 100 mm
ag3 zin Relative Sup-Inf position, in slice 0 1 normalized
ag4 zout Sup-Inf position, out of slice 0 1 normalized
ag5 rsurf Depth from patient surface 0 109.2 mm
ag6 Farc Arc factor 0 1 normalized
ag7 θ Angle relative to PTV -3.14 3.13 radians
ap1 Vptv Target volume 19.67 175.5 cm
3
ap2 E Photon Energy 6 10 MV
Group A
ag8 rst Shortest distance to stomach -23.6 165.5 mm
ag9 rbb Shortest distance to bowel bag -34.1 105.5 mm
ag10 rgtv Shortest distance to GTV -13.7 110.5 mm
Group B
ag8 rst Shortest distance to stomach -15.9 130.2 mm
ag9 rduo Shortest distance to duodenum -12.1 121.5 mm
ag10 rsb Shortest distance to small bowel -26.1 130 mm
TABLE II. Initial parameters used to build the artificial neural network dosimetric models (ANN-DMs). Geometric parameters
ag1 through ag7 and both plan parameters were common to all ANN-DMs and would be generically relevant for most treatment
sites receiving arc-based SBRT. Three site-specific geometric parameters were also included for patients in Groups A and B.
For all parameters, minimum and maximum values are provided, along with their units.
ment style, including the types of hot spots considered
permissible, OAR dose-volume histogram priorities, and
relative tradeoffs between PTV coverage and OAR spar-
ing. Separating patients into Groups A and B effectively
incorporates these two factors into the dose models with-
out having to explicitly indicate them for each patient.
E. Model Training and Validation
Multiple ANN-DMs were developed, but all were
trained and validated using data exported from the TPS
(Eclipse; Varian Medical Systems; Palo Alto, CA), in-
cluding CT images, treatment plans, structures, and
TPS-calculated dose distributions. For each individual
voxel, inputs to the ANN-DM were geometric and plan
parameters (as described above), and the single output
was a prediction of the TPS-calculated dose for that
voxel. By inputting thousands of voxels across multi-
ple patients, prediction models are established for each
ANN-DM to estimate physician-approved dose.
Patient datasets were randomly divided into two
groups: roughly 2/3rds for training, and 1/3rd for valida-
tion (19 and 10 for Group A, 9 and 5 for Group B, respec-
tively). Only voxels within 100 mm of the PTV were used
as inputs. Across all 43 patients, a total of 75,610,117
voxels were available for training and validation, with
812,908 of those voxels residing within the PTV. How-
ever, due to the highly correlated nature of TPS dose
distributions, the number of truly unique data points is
likely smaller. To lower computation times, a random
subset of 1 in every 40 voxels (2.5% of the total) was used
for training. This choice was validated by also training
models with 5%, 10%, and 25% of the total voxels, and
no significant changes were seen in the results. For each
group of patients, two ANN-DMs were computed: one
for voxels inside the PTV, and another for voxels out-
side the PTV. All computations were performed in the
MATLAB computing environment (MathWorks; Natick,
MA). To produce a model that was most accurate in the
area close to the PTV, voxels were weighted by dose (i.e.,
weight = dose/prescription) to ensure sufficient sampling
of the dose falloff region.
The majority of ANN-DMs used in this study were
composed of a feed-forward network with 25 nodes in
a single hidden layer, and they were trained using L2
regularization. Log-sigmoid functions were used for all
activation functions, and scaled conjugate gradient back-
projection was used to train each network. Other ANN
training algorithms were investigated (i.e., quasi-Newton
backprojection and conjugate gradient backprojection),
but no significant improvements to the results were seen.
To evaluate the role of neural network complexity, mul-
tiple networks with increased and decreased complexity
were also tested using a consistent set of model parame-
ters. Neural network complexity increases with increas-
ing number of hidden layers and increasing number of
nodes per layer. Here, we tested neural networks with 1
to 3 hidden layers, with each layer containing 10 to 50
nodes in each layer. Mean absolute dose error was used to
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FIG. 2. Substantial reductions in ANN-DM dose error were
achieved by creating dedicated models for each distinct group
of patients. Box plots (mean, 95% CI) of dose errors in vali-
dation datasets are shown with respect to distance from the
PTV for All Patients, Group A, and Group B. Most notable
in the dose falloff region, mean absolute dose errors were de-
creased from >30% to <5% when groups were modelled sep-
arately.
quantify any benefits gained with increasing complexity.
F. Gaussian Broadening of Target Volumes
In early efforts to train the models, we observed good
performance within the training dataset, but very poor
performance in the validation dataset. These errors were
found to originate mainly from overfitting of the volume
parameter, Vptv, which is a continuous variable, but takes
a discrete value for all voxels belonging to a single patient.
To correct for this, Gaussian noise was added to the Vptv
value seen in each voxel for a given patient. The standard
deviation of this distribution was chosen empirically to
be 10 cm3, as this was found to generate nearly contin-
uous coverage of the volume parameter space across all
patients. In this way, we were able to prevent strange
model behavior in the validation dataset.
III. RESULTS
It became evident early on in ANN-DM development
that separate models needed to be created for patients
from Group A and Group B in order to account for
the distinct treatment approaches taken by each groups
respective physician. To demonstrate this, Figure 2 il-
lustrates the substantial improvements in accuracy that
were gained by creating dedicated models for each group.
Mean absolute dose errors of >30% in the dose falloff re-
gion were reduced to <5% when each group was modelled
separately. After preliminary investigations, several dif-
ferent dose model configurations were implemented in or-
der to evaluate choices of ANN-DM structure. Two main
aspects were considered: neural network complexity, and
choices of input parameters.
A. Model Complexity
Mean absolute dose error with respect to model com-
plexity was evaluated by varying the number of hidden
layers in the network (1-3) and the number of nodes
per layer (10, 20, 30, 40, and 50). Increased neural
network complexity (i.e., more hidden layers and nodes
per layer) did not significantly improve model perfor-
mance. Although some reduction in errors could be seen
in the training dataset as the number of hidden layers
increased, those reductions were not reflected in the vali-
dation dataset. Ultimately, a consistent model structure
was chosen to include one hidden layers with 25 nodes
each. Using this structure, each ANN-DM took roughly
5 minutes to train on a standard Intel Core-i7 desktop, or
roughly 20 seconds on a commercial-grade GPU (Nvidia
Quadro M6000).
B. Relative Pertinence of Model Parameters
To quantify the relative impact each parameter had
for each dose model, parameters were individually re-
moved from each model to see how much its absence in-
creased that models mean absolute dose error. Dose er-
rors were summarized for three different regions: inside of
the PTV, within 3 cm just outside of the PTV, and more
than 3 cm outside of the PTV. Results from these tests
are provided in Table III. The most impactful parameter
was zout, which saw a 40% increase to mean absolute dose
error in the region just outside of the PTV. Nevertheless,
all other parameters included in Table III showed consid-
erable pertinence in at least one of the three regions for
either Group A or Group B.
Two input parameters from Table II were not included
in Table III because it was decided to remove them from
all dose models: E and θ. Removal was either due to
the parameter being redundant, or its removal from dose
models resulted in improved accuracy in all three regions.
For Group A, removal of the E factor reduced the models
overall error by roughly 4.5% of the prescribed dose. For
Group B, all treatment plans used 10 MV FFF beams, so
inclusion of the E parameter was unnecessary. For both
groups, inclusion of θ also resulted in increased errors in
all regions.
7Parameter Inside PTV ≤ 3 cm Outside PTV > 3 cm Outside PTV
A B A B A B
rptv3D 1.8 11.8 4.9 12.8 0.9 15.6
rptv2D 3.8 5.3 13.5 14 5 0.9
zin 2.8 4.8 12.5 8.4 5.8 4.9
zout 1.6 24.2 40.2 37.6 10.5 2.8
rsurf 7 7.7 1.7 6.9 -0.8 12.4
Farc 0.1 5.7 8.6 1.6 3.8 -7.2
Vptv 0 11.3 6.7 3.3 1.4 -5.2
rst 2.8 4.6 1.1 8.6 -1.4 9.7
rbb 0.7 – 9.9 – 10.3 –
rgtv 31.2 – 2.5 – 1.2 –
rduo – 8.7 – 0.2 – -4.2
rsb – -1.2 – 10.8 – 1.3
TABLE III. Quantifying the relative contribution of each parameter to model accuracy. Values shown are the relative increase
in mean absolute dose error (as % of Rx dose) when each parameter was removed from the dose model. Analysis was divided
into three regions: inside the PTV, within 3 cm outside of the PTV, and more than 3 cm outside of the PTV.
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C. Model Accuracy
Using the final versions of each dose model (i.e., with
E and θ removed), sample data are shown in Figure 3
for two patients, one from Group A and one from Group
B. Included are axial slices from the planning CT, their
corresponding axial dose error maps, as well as dose error
maps displayed with respect to angle and distance to the
PTV centroid. Across all patients, the maximum and
minimum dose outputs for our ANN-DMs were 36.38 Gy
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9and -1.25 Gy, respectively.
Three performance metrics - mean dose error, mean
absolute dose error, and dose error standard deviation
- were calculated for training and validation data for
Group A and Group B, and are plotted in Figure 4 with
respect to voxel distance to the PTV surface. In order to
present the entire dose fall off region, values just within
the PTV surface (i.e., negative distance from PTV val-
ues) are also shown. Overall, modelled dose distributions
displayed excellent agreement with planned dose distri-
butions. Mean dose errors were less than 5% at all dis-
tances from the PTV, while mean absolute dose error was
on the order of 5%, but no more than 10%. The magni-
tude of errors were similar between Group A and Group
B, although the mean error and mean absolute error were
both higher inside the PTV in Group A, possibly due to
the multiple dose levels used. The standard deviation
of the dose distribution quantified the distribution of er-
rors, and in both groups was similar in the training and
validation datasets.
DVH errors for training and validation data are shown
in Figure 5 for each of the primary OAR volumes used
for Group A and Group B. Models displayed good per-
formance in higher dose regions of the DVH curve, but
much larger errors were seen at lower doses. Based on
the OAR dose restraints used in this work (see Table I),
only the V33 metric could be reliably predicted.
D. Simple Dose Model Comparisons
Voxel error distributions are plotted in Figure 6 for
the final versions of each ANN-DM, the null model,
and simple linear regression models. For each, training
and validation data are both shown. Outside the PTV,
dose distributions based on linear regression dose mod-
els demonstrated much broader error ranges than ANN-
DM dose distributions. Within the PTV, the null model
was shown to underestimate the dose delivered, indicat-
ing that a noticeable region of the PTV receives more
than the nominal prescribed dose in physician-approved
clinical treatment plans.
IV. DISCUSSION
We have implemented a neural-network-based 3D dose-
prediction algorithm, and have trained/validated it using
43 clinically approved pancreatic SBRT plans. The al-
gorithm is able to predict 3D dose distributions in the
vicinity of pancreatic tumors with errors on the order
of 5%. ANN-DMs were also shown to significantly out-
perform more simple models (i.e., null model and simple
linear regression). However, there remains substantial
room for improvement of the models. One advantage of
neural network machine learning is that new information
can be incorporated with relative ease by the additional
of parameters to the model. We note that, in Figure 3c
and 3f, there is a substantial component of error related
to angle, although the addition of a single angle (i.e., θ)
parameter was insufficient to account for this difference.
One possibility is that the model may require additional
information regarding the path of each radiation beamlet
(e.g., whether there are overlying PTV or OAR voxels).
Our results demonstrate the appropriateness of arti-
ficial neural networks for this purpose. Compared to
more simple models (null models or linear regression
with feature engineering), ANN-DM displayed greatly re-
duced error (see Figure 6). The underlying structure
of planned radiotherapy dose distributions is inherently
multi-dimensional, and modeling these distributions re-
quires a sophisticated approach. Additionally, we found
no benefit to more complex models (e.g. increasing the
complexity of the neural network structure).
As has been demonstrated, artificial neural network
dose models can be used to reliably predict physician-
approved dose distributions for patients receiving pan-
creatic SBRT. Furthermore, the predictive accuracy of
these dose models was significantly improved when dedi-
cated models were developed for specific treatment styles.
As such, despite being implemented for the same treat-
ment site using similar dose constraints, we have shown
that neural networks are capable of adapting to differ-
ent treatment protocols for the same site. This speci-
ficity is important, because one motivating force behind
knowledge-based planning is to somehow quantify and
characterize the essential aspects of high-quality treat-
ment plans. Theoretically, one could obtain treatment
plans from institutions boasting the best treatment out-
comes, and train ANN-DMs to predict the optimal dose
distributions for each new patient. In addition to pro-
moting high-quality radiation therapy, such dose models
could be used to ensure adherence to treatment protocols
in large-scale clinical trials. Practically, an ANN-DM val-
idation scheme could be implemented with relative ease,
given that the model could be trained centrally by the
trial coordinates and distributed to member institutions
for local calculation and validation.
It should be noted that, although we have shown
that ANN-DMs are capable of predicting desirable dose
distributions, these models alone do not describe how
to deliver these dose distributions. Yet, because these
models are based off of previously delivered treatment
plans, they are unlikely to propose outrageously idealis-
tic dose distributions. ANN-DMs trained using real plans
should produce deliverable or near-deliverable dose dis-
tributions. Hence, one could envision a clinical workflow
where ANN-DMs are used initially to predict a physician-
approved dose distribution for each patient. With this
initial head start, dosimetrists can then focus their ef-
forts on refining each plan.
In addition, neural networks are not infallible, and
should not be used to autonomously guide treatment.
For example, neural networks can be susceptible to ex-
trapolation errors whenever a new case is presented that
resides outside the range of the training dataset (e.g., a
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FIG. 6. Voxel dose errors as a percentage of the prescribed dose are shown for Groups A and B. Top: errors from ANN-DMs
are plotted alongside errors from simple linear regression models outside the PTV. Bottom: errors from ANN-DMs are plotted
alongside errors from the null model inside the PTV.
PTV larger or smaller than was seen during training).
Thus, as optimal plans for outlier cases accumulate, they
can be used to further train the model, thereby expand-
ing the range of values the network is proficient in. An-
other drawback of ANN-DM is that they do not directly
calculate (and are not trained based on) DVH parame-
ters, which are the most clinically relevant. The ANN-
DMs developed here were trained according to the dose
errors seen for each voxel. On the other hand, DVH
errors are by their nature based off of cohorts of many
voxels. However, modifications to the current approach
might improve DVH accuracy. Theoretically, one could
define new input parameters that might better represent
the relationship between the PTV and OARs. For ex-
ample, inversely optimized arc-based treatment plans are
unlikely to deliver dose through portions of the arc where
the PTV and OARs are in line with one another. Ergo,
as determined by the geometries of the PTV, the OARs,
and the treatment machine, one could delineate regions
of patient anatomy that are less likely to be irradiated.
With these regions defined, a Boolean geometric parame-
ter could be used to indicate whether or not a given voxel
was in a region that was unlikely to be irradiated.
V. CONCLUSIONS
Artificial neural network dose models have been devel-
oped to reliably predict physician-approved dose distri-
butions for pancreatic SBRT patients. The influence of
different neural network features, including network com-
plexity and input parameter choices, have been investi-
gated and networks have been optimized accordingly. It
is particularly noteworthy that significant predictive ac-
curacy was gained by building separate ANN-DMs for
separate treatment protocols. As such, using consensus
guidelines for high-quality treatment plans, neural net-
work dose models could potentially be trained for the
11
purposes of patient-specific plan quality validation. The
inclusion of such a validation step could help promote
protocol compliance, be it for a single institution, or for
a large-scale clinical trial.
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